A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer

← catalyst calendar

NCT07505771 · readout ≤ 1,230 d

Sponsored by Immunome, Inc. (industry) · IMNM — their whole pipeline →.

Phase

Early Phase 1

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

105estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-06-19

actual

When the study began enrolling

Primary completion

Dec 2029

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Dec 2034

estimated

The whole study's end, after follow-up

First posted

2026-04-01

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-29

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Solid Malignancies

Intervention

Drug: 177Lu-IM-3050

Primary outcomes

what the primary-completion date above is the date OF

Safety and tolerability of 177Lu-IM-3050 in participants with advanced solid tumors as measured by incidence of treatment emergent adverse events (TEAEs)

measured From first dose of 177Lu-IM-3050 through at least 42 days following last dose of study treatment serious; up to approximately 5 years

Determine the recommended dose of 177Lu-IM-3050 for further development

measured From first dose of 177Lu-IM-3050 to 42 days following last dose of study treatment; up to approximately 5 years

Permalink · IMNM's whole pipeline · Catalyst calendar · Every registered study · What changed